Top Markets
Coin of the day
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
Rang în acțiuni #2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Preț acțiune
$43.48
Capitalizare de piață
$8.97B
Schimbare (1 zi)
0.37%
Schimbare (1 an)
192.01%
Țară
US
Tranzacționează Immunovant, Inc. (IMVT)

Categorie

Istoric al prețului acțiunii pentru Immunovant, Inc. (IMVT)
Cel mai mare preț de închidere: $42.53 pe 2026-08-01

Cel mai mic preț de închidere: $9.88 pe 2019-06-01
Istoric al prețului acțiunii pentru Immunovant, Inc. din 2019 până în 2026
Evoluția anuală a prețului acțiunii
An Performanță
2026 (TTM) 8.62%
2025 -7.38%
2024 -34.45%
2023 163.89%
2022 99.44%
2021 -84.02%
2020 273.47%
2019 0.00%
Prețul acțiunii pentru companii similare sau concurente
Companie Preț acțiune Variație 1an% Țara
$553.95 42.42%
US
$1.02K 50.63%
NL
$157.63 521.81%
US
$122.47 -12.71%
AU
$772.27 8.67%
CH